RECENT NEWS (Jan 26th 2017): Ossianix receives milestone payment from Lundbeck for blood-brain barrier (BBB) antibody delivery technology!!!
Read the Financial Times coverage here.
About the Company
The company is headquartered in the University City Science Center in downtown Philadelphia and has research laboratories at the Stevenage Bioscience Catalyst in Stevenage, Herts, UK. Ossianix was founded by Frank S Walsh, Corey Goodman and Lynn Rutkowski who have had distinguished careers in academia, Pharma and Biotech and bring a wealth of experience to the problem of delivering the next generation of Biologics products. The company started operations in 2012 with funding from Lundbeck Pharmaceuticals, BioAdvance and the ALS Association. Current programs focus on autoimmunity, neurodegereration, ALS, pain and botulism.